Top Data Analytics Companies in Boston, MA (148)

Strong Revenue Growth: Financial disclosures indicate total revenue increased from 2024 to 2025 alongside higher total reported sales, while operating earnings rose sharply. Together these patterns suggest momentum in top line and core operating performance.

Investor Backing & Capital Strength: Total adjusted capital increased from $33.2B to $34.4B, and an estimated $2.9B dividend was approved for eligible policyowners, supported by very strong insurer financial-strength ratings. These signals point to a robust balance sheet that underpins stability and growth capacity.

Diversified Revenue Streams: Expansion was described as broad-based across insurance, annuities, institutional solutions, and wealth management, with client assets in wealth management reaching a record $312B and total AUM at $584B. This mix reduces reliance on any single line of business and supports continued scale.

Investor Backing & Capital Strength: A majority investment by Nordic Capital and a $125 million financing from Vista Credit Partners are described as fueling accelerated innovation and scale. These developments signal ample capital access to support ongoing expansion.

Product Line Growth: The CareJourney acquisition and subsequent launches of expanded suites (e.g., Ascent, CareJourney, LifeScience) and AI-enabled capabilities broaden the platform’s functionality. These moves indicate a deliberate build-out of offerings across providers, payers, and life sciences.

Market Expansion: New customer business reportedly added more than 2.25 million value-based lives and brought the ecosystem to over 170 million patient records, with the combined portfolio approaching 200 organizations. Active customer and partner engagement at Aggregate 2025 further suggests a deepening commercial footprint.

Strong Revenue Growth: Revenue is growing at double-digit rates, with Q2 2026 up 27% year over year and first-half 2026 up about 25%. Management also raised full-year 2026 guidance to $94–96 million, implying approximately 22–24% growth.

Market Expansion: U.S. activity accelerated, with U.S. analysis volume up 60% year over year in Q2 2026 and major health-system additions. Core genomics customers increased to 542 as of June 30, 2026, from 490 a year earlier.

Customer Loyalty & Retention: Net dollar retention improved to 117% in Q2 2026 (versus 107% a year earlier), indicating greater spending within the installed base. Platform usage also reached a record 115,000 analyses in Q2 2026, up 22% year over year.

Profitability: Profitability is considered to be improving, with Q2 2026 ex-TAC gross profit up 11.8% year over year, adjusted EBITDA up 22.8%, and net income turning positive. Management also raised full-year guidance for ex-TAC gross profit and adjusted EBITDA despite slower headline revenue.

Innovation-Driven Growth: AI-driven initiatives and newer products such as the Realize platform and DeeperDive are described as key growth engines, contributing to faster ex-TAC gross-profit expansion than total revenue. Taboola News’ broad reach across 80+ countries and 2,000+ publishers further supports product-led expansion.

Strategic Partnerships: Expanded publisher and device relationships, including Fox News and OEM partners like Samsung, Xiaomi, and Motorola, are seen as enlarging distribution and advertiser access. Long-standing large-scale partnerships (e.g., Yahoo-related supply) have historically supported network growth and monetization.

Strong Revenue Growth: ARR is reported to have more than tripled between 2021 and 2025 while profitability improved. AI-related ARR also rose from $20 million in Q1 2025 to $109 million in Q1 2026, reinforcing momentum.

Market Expansion: Reported enterprise customers grew from 1,200+ in 2024 to 1,500+ in 2025, and platform reach expanded from 15 million to 25 million endpoints/employees. International moves, including plans for Japan and South America, indicate continued geographic expansion.

Investor Backing & Capital Strength: A majority investment by Vista Equity Partners at an approximately $3 billion valuation in 2025 signals strong external confidence. This transaction follows years of scaling and provides capital support for the next phase.

Strong Revenue Growth: Revenue is advancing at double-digit rates across multiple periods, with FY2026 revenue rising 19% to about $2.02B and fiscal Q1 FY2027 revenue up 16% to $555M. ARR also increased 17% in the latest quarter, reinforcing breadth of growth in a subscription model.

Healthy Cash Flow: Cash generation is robust, including approximately $529M in free cash flow for FY2026 and operating cash flow of roughly $306M in Q1 FY2027. These indicators suggest expansion is supported by solid liquidity rather than heavy cash burn.

Product Line Growth: Log management is scaling rapidly, with annualized consumption reaching about $200M in Q1 FY2027 and growing at more than 100% year over year. Investment in AI-powered operations and platform capabilities is extending the growth runway.

Strong Revenue Growth: Company-reported results indicate double-digit revenue growth in FY 2024 and continued expansion in recurring revenue. Feedback suggests growth is broad-based, spanning new customer wins and increased usage.

Profitability: Operating updates describe the business as profitable and cash-flow positive while scaling. This combination points to growth supported by financial discipline rather than spend-at-all-costs expansion.

Customer Loyalty & Retention: Account activity shows widespread expansions across the installed base alongside high retention. Feedback suggests the land-and-expand motion is a meaningful contributor to durable growth.

Market Expansion: Customer reach is described as rising from 500+ organizations in late 2025/early 2026 to 1,000+ by September 2026, alongside a sharp increase in engineering data analyzed (100M+ pull requests across 275,000+ engineers). Feedback suggests this reflects broadening adoption and presence across the target market.

Innovation-Driven Growth: The platform expanded into AI-focused engineering intelligence, launching tools to measure coding-assistant adoption, productivity, and ROI, and reporting 90M AI prompts and 150T tokens analyzed by September 2026. Feedback suggests this product evolution positions the company to capture demand in a fast-growing segment.

Strong Revenue Growth: Directional estimates indicate revenue increased from about $13M in 2022 to $21M in 2023 and $31.9M in 2024. While not audited, these figures imply meaningful commercial momentum.

Market Expansion: Evidence indicates the 2026 acquisition of Urgently and added commercial roles broaden Agero’s reach across automotive, fleet, rental, and insurance, taking the combined platform to about 150 million vehicles and roughly 13–14 million annual service events. New and renewed programs further extend activity across roadside assistance, claims, and mobility services.

Strong Market Position & Advantage: Company materials describe service to approximately 150 million drivers, relationships with six of the top ten insurers, and a nationwide network of 8,000+ providers. External recognition such as Frost & Sullivan’s 2025 North American Company of the Year reinforces a durable competitive position in digitalized roadside assistance.

Strategic Partnerships: Renewals and wins like Hagerty and Virginia Farm Bureau Insurance, plus collaborations such as MOTER, point to deep, ongoing enterprise relationships. These ties support recurring service volumes and cross-sell opportunities across roadside, accident management, and connected-vehicle offerings.

Strong Revenue Growth: Recent financial results highlight sustained top-line expansion with rising quarterly revenue and management increasing full‑year guidance, indicating momentum across 2025 and into 2026.

Diversified Revenue Streams: Growth is coming from both diagnostics and data licensing/AI applications, with testing volumes and data contracts expanding rather than reliance on a single line of business.

Customer Loyalty & Retention: Reported net revenue retention above 100% and sizable remaining contract value suggest existing pharmaceutical customers are deepening engagements.

Strong Revenue Growth: Revenue is rising steadily, including 11% year-over-year growth to $192.8 million in Q2 2026 and 7% growth for full-year 2025. The step-up from 6% growth in Q1 2026 to 11% in Q2 indicates accelerating momentum.

Profitability: Adjusted EBITDA increased 30% year over year in Q2 2026 as margin expanded from 34% to 37%, signaling operating leverage. Net income also improved to $19.4 million from $11.1 million year over year in that quarter.

Healthy Cash Flow: Guidance points to free-cash-flow growth in the high-40% range for 2026 alongside adjusted EBITDA growth of more than 20%. Operating cash flow reached $57.4 million in Q2 2026.

Investor Backing & Capital Strength: Capital raising includes a $372 million Series D in 2024 with participation from Sanofi, bringing total funding above $600 million. The stated use of proceeds was to expand the drug pipeline and AI platform, indicating a strong financial base for growth.

Product Line Growth: The portfolio has expanded through multiple in-licensing deals in 2025–2026 and now spans preclinical, Phase 1, and Phase 2 programs. Tangible execution includes dosing the first participant in the BLKR201 Phase 1 trial in June 2026, only months after licensing the asset.

Strategic Partnerships: High-profile collaborations include work with Sanofi and OpenAI to build AI tools for drug development, alongside a Sanofi licensing agreement for gusacitinib with significant potential milestone value. These relationships reinforce external validation and create pathways to scale development.

Strong Hiring & Retention: Employee headcount is increasing over the 2023–2026 period, indicating ongoing hiring momentum. Feedback suggests workforce expansion is sustained even if the pace has moderated recently.

Market Expansion: A new Jakarta office was opened in 2026 to deepen engagement across Southeast Asia. Operations span dozens of offices in many countries, supporting customers in more than 80 countries.

Innovation-Driven Growth: New offerings such as the Data Studio AI Assistant and continued development of healthcare interoperability products point to active product investment. Feedback suggests AI and healthcare enhancements are a current strategic focus.

Strong Market Position & Advantage: The company is repeatedly characterized as a top-tier, scale leader in global first-party panels and large-scale fieldwork, appearing among major industry rankings and serving thousands of clients worldwide. Its panel reach and ability to deliver fast, multi-market incidence-finding are highlighted as clear execution advantages.

Investor Backing & Capital Strength: After a court-approved restructuring, the company emerged with reduced leverage and fresh financing to support its roadmap. These actions are framed as stabilizing the balance sheet and extending runway for long-term programs.

Future-Ready Strategy: Management articulated a multi-year transformation with investments in product, quality certifications, and go-to-market leadership. New offerings and integrations (e.g., activation workflows and AI-driven quality features) indicate continued movement toward higher-value use cases.